Novasep and Lysogene have entered an agreement for the development and manufacturing of LYS-GM101, an AAVrh10-based gene therapy drug candidate for the treatment of GM1 gangliosidosis, a rare neuronopathic lysosomal storage disorder.   With this collaboration, the two companies consolidate their long-lasting partnership initiated with the development and manufacturing of Lysogene’s lead gene therapy product, LYS-SAF302, currently in clinical phase 2/3.   “Following the successful rel...